The narrow EPS beat and guidance raise suggest underlying strength, particularly in Innovative Medicine. The dividend increase reinforces JNJ's commitment to shareholder returns, making it attractive for income-focused investors.
JNJ drugs
JNJ drug pipeline →- ▲ DARZALEX 4/10 Approved (multiple FDA-approved multiple-myeloma indications); additional label-expansion Phase 3 studies completed.
- ◆ IMAAVY 4/10 Approved (first indication); NDA under FDA review for wAIHA
- ● SPRAVATO 4/10 Approved
- ▲ TREMFYA 4/10 Approved (marketed); BLA 761061 with multiple supplemental approvals; further Phase 3 label-expansion studies ongoing/co
- ▲ CARVYKTI 3/10 Approved (marketed); ongoing Phase 2/3 studies
- 12 more · All JNJ drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 14 $240.01entry
- T+1 · 7mo ago −0.68%α −1.45% · $238.38
- T+5 · 7mo ago −5.85%α −7.24% · $225.97
- T+20 · 6mo ago −7.74%α −14.04% · $221.43
- T+60 · 4mo ago +7.96%α −0.29% · $259.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Johnson & Johnson reported Q1 2026 earnings with adjusted EPS of $2.70, narrowly beating consensus of $2.68, and raised full-year guidance. The company also announced a 3.1% dividend increase, marking its 64th consecutive annual dividend hike.
Key Financial Metrics
Key Facts
- Adjusted EPS of $2.70 vs. consensus of $2.68
- Raised full-year 2026 guidance for adjusted EPS to $11.55 at midpoint
- Declared 3.1% dividend increase to $1.34 per share
- Innovative Medicine segment grew 11.2% with strong performance in oncology and neuroscience
Financial Impact
Adjusted EPS beat by $0.02 and raised guidance
Risk Factors
- GAAP EPS of $2.14 missed expectations due to litigation-related charges
- Future performance depends on execution of restructuring programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000200406-26-000076 |
| Document: a2026q1exhibit991.htm | 0000200406-26-000076 |
| Document: jnj-20260414.htm | 0000200406-26-000076 |
| Document: a2026q1exhibit993.htm | 0000200406-26-000076 |
| Document: 0000200406-26-000076-index-headers.html | 0000200406-26-000076 |
| Document: 0000200406-26-000076-index.html | 0000200406-26-000076 |
| Document: 0000200406-26-000076.txt | 0000200406-26-000076 |
| 8-K Data (Synthetic) | 0000200406-26-000076 |
Track record
21 reports on JNJ
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +13.24% at T+60 after the May 13, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry $289.75 Now $282.55 −2.48% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $283.52 Now $282.55 −0.34% settles Feb 10
- Oct 13, 20264w ago 8-K Mixed 6/10 Entry $248.61 Now $282.55 +13.65% settles Jan 8
- Sep 30, 20266w ago Court Ruling Bullish 6/10 Entry $258.66 Now $282.55 +9.24% settles Dec 28
- Sep 24, 20267w ago Court Ruling Neutral 3/10 Entry $271.22 Now $282.55 +4.18% settles Dec 21
- Sep 9, 20269w ago Court Ruling Neutral 1/10 Entry $266.35 Now $282.55 +6.08% settles Dec 4
- Aug 18, 202612w ago Insider Cluster Neutral 2/10 Entry $273.41 to $283.52 Now $282.55 +3.34% ▲ +3.70% +5.25% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 2/10 Entry $262.37 to $280.78 Now $282.55 +7.69% ▲ +7.02% +9.96% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 3/10 Entry $261.81 to $266.17 Now $282.55 +7.92% ▲ +1.67% +4.08% vs SPY
- Aug 7, 202614w ago Court Ruling Bearish 4/10 Entry $261.81 to $266.17 Now $282.55 −7.92% ▼ −1.67% −4.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers